L-carnitine in haemodialysed patients. Changes in lipid pattern

Area of Science:

• Biochemistry
• Nephrology
• Clinical Nutrition

Background:

• Dialysis patients experience carnitine deficiency due to losses during treatment.
• This deficiency is linked to impaired lipid metabolism and cardiovascular risk factors.
• Patients may present with dyslipidemia or altered lipoprotein profiles, even if seemingly normolipidemic.

Purpose of the Study:

• To investigate the effect of l-carnitine supplementation on lipid profiles in dialysis patients.
• To assess changes in high-density lipoprotein (HDL) cholesterol and lipoprotein ratios.
• To evaluate the impact on patients with altered coronary risk factors despite normal lipid levels.

Main Methods:

• A randomized, placebo-controlled trial was conducted.
• Participants were apparently normolipaemic dialysis patients with abnormal coronary risk factors.
• Lipid profiles, including HDL-cholesterol and beta:alpha lipoprotein ratio, were measured over 30 days.

Main Results:

• Placebo treatment showed no significant changes in lipid profiles.
• L-carnitine supplementation led to a statistically significant increase in HDL-cholesterol.
• L-carnitine also reduced pre-beta-lipoproteins and decreased the beta:alpha lipoprotein ratio.

Conclusions:

• L-carnitine supplementation can positively modulate lipid metabolism in dialysis patients.
• It may help improve cardiovascular risk factors by enhancing HDL-cholesterol and altering lipoprotein patterns.
• Carnitine therapy offers a potential strategy to manage dyslipidemia in chronic kidney disease patients undergoing dialysis.